Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1985 Nov;52(5):757–763. doi: 10.1038/bjc.1985.254

Ability of sera from mice treated with Ge-132, an organic germanium compound, to inhibit experimental murine ascites tumours.

F Suzuki, R R Brutkiewicz, R B Pollard
PMCID: PMC1977232  PMID: 3933536

Abstract

Sera from C57Bl/6 mice treated orally with Ge-132 exhibited antitumour activity against Ehrlich (allogeneic) and RL male 1 (syngeneic) ascites tumours in BALB/c mice. Sera obtained from mice 24 h after Ge-132 administration displayed the greatest antitumour effect and this was dose dependent. Sera prepared from mice 12, 36, or 48 h after Ge-132 treatment had no protective effect. Circulating interferon (IFN) was induced at 24 h after administration of Ge-132 but was not detected in the sera at 12, 36, or 48 h after administration. The antiviral activity of sera from Ge-132-treated mice was inactivated by treatments with trypsin, low pH, and anti-IFN gamma antiserum. The inactivated preparations of serum IFN induced by Ge-132 did not exhibit antitumour activity when administered to tumour-bearing mice. These results suggest that antitumour activity in the sera of Ge-132-treated mice may be expressed through activities of Ge-132-induced lymphokine(s), such as IFN gamma.

Full text

PDF
757

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chang T. W., Testa D., Kung P. C., Perry L., Dreskin H. J., Goldstein G. Cellular origin and interactions involved in gamma-interferon production induced by OKt3 monoclonal antibody. J Immunol. 1982 Feb;128(2):585–589. [PubMed] [Google Scholar]
  2. Chaouat G., Howard J. G. Influence of reticuloendothelial blockade on the induction of tolerance and immunity by polysaccharides. Immunology. 1976 Feb;30(2):221–227. [PMC free article] [PubMed] [Google Scholar]
  3. Crane J. L., Jr, Glasgow L. A., Kern E. R., Youngner J. S. Inhibition of murine osteogenic sarcomas by treatment with type I or type II interferon. J Natl Cancer Inst. 1978 Sep;61(3):871–874. [PubMed] [Google Scholar]
  4. Hibbs J. B., Jr Activated macrophages as cytotoxic effector cells. Transplantation. 1975 Jan;19(1):77–81. doi: 10.1097/00007890-197501000-00015. [DOI] [PubMed] [Google Scholar]
  5. Kasahara T., Hooks J. J., Dougherty S. F., Oppenheim J. J. Interleukin 2-mediated immune interferon (IFN-gamma) production by human T cells and T cell subsets. J Immunol. 1983 Apr;130(4):1784–1789. [PubMed] [Google Scholar]
  6. Kleinschmidt W. J., Schultz R. M. Similarities of murine gamma interferon and the lymphokine that renders macrophages cytotoxic. J Interferon Res. 1982;2(2):291–299. doi: 10.1089/jir.1982.2.291. [DOI] [PubMed] [Google Scholar]
  7. Matsubara S., Suzuki M., Suzuki F., Ishida N. The induction of viral inhibitor(s) in mice treated with biological and synthetic immunopotentiators. Microbiol Immunol. 1980;24(1):87–90. doi: 10.1111/j.1348-0421.1980.tb00565.x. [DOI] [PubMed] [Google Scholar]
  8. Mizushima Y., Shoji Y., Kaneko K. Restoration of impaired immunoresponse by germanium in mice. Int Arch Allergy Appl Immunol. 1980;63(3):338–339. doi: 10.1159/000232645. [DOI] [PubMed] [Google Scholar]
  9. Männel D. N., Falk W. Interferon-gamma is required in activation of macrophages for tumor cytotoxicity. Cell Immunol. 1983 Jul 15;79(2):396–402. doi: 10.1016/0008-8749(83)90082-5. [DOI] [PubMed] [Google Scholar]
  10. Mühlradt P. F., Opitz H. G. Clearance of interleukin 2 from the blood of normal and T cell-depleted mice. Eur J Immunol. 1982 Nov;12(11):983–985. doi: 10.1002/eji.1830121117. [DOI] [PubMed] [Google Scholar]
  11. Nakayama E., Uenaka A. Effect of in vivo administration of Lyt antibodies. Lyt phenotype of T cells in lymphoid tissues and blocking of tumor rejection. J Exp Med. 1985 Feb 1;161(2):345–355. doi: 10.1084/jem.161.2.345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Opitz H. G., Opitz U., Hewlett G., Schlumberger H. D. A new model for investigations of T-cell functions in mice: differential immunosuppressive effects of two monoclonal anti-Thy-1.2 antibodies. Immunobiology. 1982 Feb;160(5):438–453. doi: 10.1016/S0171-2985(82)80007-7. [DOI] [PubMed] [Google Scholar]
  13. Osborne L. C., Georgiades J. A., Johnson H. M. Classification of interferons with antibody to immune interferon. Cell Immunol. 1980 Jul 15;53(1):65–70. doi: 10.1016/0008-8749(80)90426-8. [DOI] [PubMed] [Google Scholar]
  14. Osborne L. C., Georgiades J. A., Johnson H. M. Large-scale production and partial purification of mouse immune interferon. Infect Immun. 1979 Jan;23(1):80–86. doi: 10.1128/iai.23.1.80-86.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Pace J. L., Russell S. W., Torres B. A., Johnson H. M., Gray P. W. Recombinant mouse gamma interferon induces the priming step in macrophage activation for tumor cell killing. J Immunol. 1983 May;130(5):2011–2013. [PubMed] [Google Scholar]
  16. Roberts W. K., Vasil A. Evidence for the identity of murine gamma interferon and macrophage activating factor. J Interferon Res. 1982;2(4):519–532. doi: 10.1089/jir.1982.2.519. [DOI] [PubMed] [Google Scholar]
  17. Salvin S. B., Youngner J. S., Nishio J., Neta R. Tumor suppression by a lymphokine released into the circulation of mice with delayed hypersensitivity. J Natl Cancer Inst. 1975 Nov;55(5):1233–1236. doi: 10.1093/jnci/55.5.1233. [DOI] [PubMed] [Google Scholar]
  18. Sonnenfeld G., Mandel A. D., Merigan T. C. In vitro production and cellular origin of murine type II interferon. Immunology. 1979 Apr;36(4):883–890. [PMC free article] [PubMed] [Google Scholar]
  19. Suzuki F., Pollard R. B. Mechanism for the suppression of gamma-interferon responsiveness in mice after thermal injury. J Immunol. 1982 Nov;129(5):1811–1815. [PubMed] [Google Scholar]
  20. Suzuki F., Pollard R. B. Prevention of suppressed interferon gamma production in thermally injured mice by administration of a novel organogermanium compound, Ge-132. J Interferon Res. 1984 Spring;4(2):223–233. doi: 10.1089/jir.1984.4.223. [DOI] [PubMed] [Google Scholar]
  21. Torres B. A., Farrar W. L., Johnson H. M. Interleukin 2 regulates immune interferon (IFN gamma) production by normal and suppressor cell cultures. J Immunol. 1982 May;128(5):2217–2219. [PubMed] [Google Scholar]
  22. Weigent D. A., Stanton G. J., Johnson H. M. Interleukin 2 enhances natural killer cell activity through induction of gamma interferon. Infect Immun. 1983 Sep;41(3):992–997. doi: 10.1128/iai.41.3.992-997.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Wong C. Y., Woodruff J. J., Woodruff J. F. Generation of cytotoxic T lymphocytes during coxsackievirus B-3 infection. III. Role of sex. J Immunol. 1977 Aug;119(2):591–597. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES